Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Dupuytren's contracture Stories

2012-09-05 02:31:27

MALVERN, Pa., Sept. 5, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced a safety update following 30 months of post-approval use in the U.S. of XIAFLEX® for the treatment of adult Dupuytren's contracture patients with a palpable cord. After approximately 27,000 injections administered to approximately 21,000 patients in the U.S., there was no clinically meaningful change in the nature of events expected...

2012-09-04 02:29:31

LYNBROOK, N.Y., Sept. 4, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the following two upcoming investor conferences in September: Rodman & Renshaw 14th Annual Healthcare ConferenceMonday, September 10, 2012 at 11:40 am EDTNew...

2012-08-29 02:25:25

LYNBROOK, N.Y., Aug. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in Europe and Eurasia, today announced that Thomas L. Wegman, President of BioSpecifics, will present at the Stifel Nicolaus Weisel Healthcare Conferences 2012 at 9:45 am EDT on Wednesday, September 5, 2012 in Boston, MA. The live webcast of this presentation may...

2012-08-27 14:21:14

LYNBROOK, N.Y., Aug. 27, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX(®) in Europe and Eurasia, today announced that additional data will be presented from the Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium) and known as IMPRESS (The...

2012-08-27 02:24:25

MALVERN, Pa., Aug. 27, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX® (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD). These...

2012-08-09 02:29:01

LYNBROOK, N.Y., Aug. 9, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in Europe and Eurasia, today announced its financial results for the second quarter ended June 30, 2012 and provided a corporate update. "We are very pleased with the clinical and regulatory progress of XIAFLEX in recent months and are excited about the upcoming...

2012-08-02 02:31:34

LYNBROOK, N.Y., Aug. 2, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in Europe and Eurasia, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, August 9, 2012 to report its second quarter 2012 financial results and provide a corporate update. In order to participate in the...

2012-07-30 02:25:34

MALVERN, Pa., July 30, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive top-line data from its open-label phase IIIb trial evaluating XIAFLEX® for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. The Company enrolled 60 patients at eight sites throughout the U.S. and Australia. In the third quarter of 2012, Auxilium expects to begin a larger study with XIAFLEX for the...

2012-07-09 06:27:59

MALVERN, Pa. and LAVAL, Quebec, July 9, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Actelion Pharmaceuticals Canada Inc. announced today that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren's contracture in adults with a palpable cord in Canada. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )...

2012-06-26 10:24:38

LYNBROOK, N.Y., June 26, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX® in Europe and Eurasia, today announced that it has initiated its Phase II trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of human lipoma. Human lipomas are encapsulated deposits of benign fat often detected as bulges under the skin and are...